Evolving concepts in meningioma management in the era of genomics.

Autor: Hsieh AL; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Bi WL; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Ramesh V; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Brastianos PK; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Central Nervous System Metastasis Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Plotkin SR; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2024 Aug 01; Vol. 130 (15), pp. 2586-2600. Date of Electronic Publication: 2024 May 16.
DOI: 10.1002/cncr.35279
Abstrakt: Meningioma is the most common type of primary brain tumor. Surgical resection followed by surveillance is the first-line treatment for the majority of symptomatic meningiomas; however, recent advances in molecular sequencing, DNA methylation, proteomics, and single-cell sequencing provide insights into further characterizing this heterogeneous group of tumors with a wide range of prognoses. A subset of these tumors are highly aggressive and cause severe morbidity and mortality. Therefore, identifying those individuals with a poor prognosis and intervening are critical. This review aims to help readers interpret the molecular profiling of meningiomas to identify patients with worse prognoses and guide the management and strategy for surveillance.
(© 2024 American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: